Ecubectedin (PM54)
Advanced Solid Tumors
Key Facts
About PharmaMar
Founded in 1986, PharmaMar's mission is to harness marine biodiversity to create life-changing oncology therapies. Its key achievement is the development and global commercialization of Yondelis® (trabectedin), a first-in-class drug for soft tissue sarcoma and ovarian cancer, which provides a revenue foundation. The company's strategy leverages its proprietary marine discovery platform to build a sustainable pipeline of novel small molecules, focusing on areas of high unmet need in oncology. PharmaMar operates as a fully integrated entity, controlling the entire process from research to sales.
View full company profileTherapeutic Areas
Other Advanced Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NT219 | Purple Biotech | Phase 1/2 |
| INDP-101 | Indaptus Therapeutics | Phase 1 |
| PM14 | PharmaMar | Phase 1/2 |
| AP-202 | Advance Pharmaceutical | Phase 1/2 |
| BI-1808 | BioInvent International | Phase 1/2a |
| GIGA-564 | GigaGen | Phase 1 |
| Venadaparib (IDX-1197) | Idience | Phase 1a |
| VET3-TGI | KaliVir Immunotherapeutics | Phase 1 |
| IT-141 (Etoposide IVECT™) | Intezyne | Phase 1 |
| NC318 | NextCure | Phase 1/2 |
| VisAcT (18F-AraG) Imaging in Solid Tumors | CellSight Technologies | Phase 1/2 |
| PhOx430 | Phost'in Therapeutics | Phase 1/2 |